Desformylflustrabromine (dFBr) and [3H]dFBr-Labeled Binding Sites in a Nicotinic Acetylcholine Receptor.

@article{Hamouda2015DesformylflustrabromineA,
  title={Desformylflustrabromine (dFBr) and [3H]dFBr-Labeled Binding Sites in a Nicotinic Acetylcholine Receptor.},
  author={Ayman K Hamouda and Ze-Jun Wang and Deirdre S. Stewart and Atul D Jain and Richard A Glennon and Jonathan B. Cohen},
  journal={Molecular pharmacology},
  year={2015},
  volume={88 1},
  pages={1-11}
}
Desformylflustrabromine (dFBr) is a positive allosteric modulator (PAM) of α4β2 and α2β2 nAChRs that, at concentrations >1 µM, also inhibits these receptors and α7 nAChRs. However, its interactions with muscle-type nAChRs have not been characterized, and the locations of its binding site(s) in any nAChR are not known. We report here that dFBr inhibits human muscle (αβεδ) and Torpedo (αβγδ) nAChR expressed in Xenopus oocytes with IC50 values of ∼ 1 μM. dFBr also inhibited the equilibrium binding… CONTINUE READING